Rationale for combination therapy of chronic myelogenous leukaemia with imatinib and irradiation or alkylating agents: implications for pretransplant conditioning
The tyrosine kinase activity of the BCR-ABL oncoprotein results in reduced apoptosis and thus prolongs survival of chronic myelogenous leukaemia cells. The tyrosine kinase inhibitor imatinib (formerly STI571) was reported to selectively suppress the proliferation of BCR-ABL-positive cells. Assuming...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
2002
|
| In: |
British journal of cancer
Year: 2002, Volume: 86, Issue: 9, Pages: 1487-1493 |
| ISSN: | 1532-1827 |
| DOI: | 10.1038/sj.bjc.6600242 |
| Online Access: | Resolving-System, lizenzpflichtig, Volltext: https://doi.org/10.1038/sj.bjc.6600242 Verlag, lizenzpflichtig, Volltext: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2375375/ 
|
| Author Notes: | J Topaly, S Fruehauf, A D Ho, W J Zeller |
| Summary: | The tyrosine kinase activity of the BCR-ABL oncoprotein results in reduced apoptosis and thus prolongs survival of chronic myelogenous leukaemia cells. The tyrosine kinase inhibitor imatinib (formerly STI571) was reported to selectively suppress the proliferation of BCR-ABL-positive cells. Assuming that imatinib could be included in pretransplantation conditioning therapies, we tested whether combinations of imatinib and γ-irradiation or alkylating agents such as busulfan or treosulfan would display synergistic activity in BCR-ABL-positive chronic myelogenous leukaemia BV173 and EM-3 cell lines. Further, primary cells of untreated chronic myelogenous leukaemia patients were assayed for colony forming ability under combination therapy with imatinib. Additionally, the cytotoxic effect of these combinations on BCR-ABL-negative cells was investigated. |
|---|---|
| Item Description: | Gesehen am 13.01.2022 |
| Physical Description: | Online Resource |
| ISSN: | 1532-1827 |
| DOI: | 10.1038/sj.bjc.6600242 |